Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease

New England Journal of Medicine

Volumn 340, Issue 10, 1999, Pages 757-763

  Friedman, Joseph H ^a  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CLOZAPINE; PLACEBO; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART INFARCTION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; TREATMENT OUTCOME;

EID: 0033545542     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903113401003     Document Type: Article

References (69)

1. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol 1991;14:283-95.
2. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, eds. Behavioral neurology of movement disorders. Vol. 65 of Advances in neurology. New York: Raven Press, 1995:115-38.
3. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-9.
4. Carter JH, Stewart BJ, Archold PG. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 1998;13:20-8.
5. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment in Parkinson's disease. Acta Neurol Scand 1991;84:111-3.
6. Friedman JH. Management of psychosis in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. 2nd ed. rev. New York: Marcel Dekker, 1995:521-32.
7. Goetz CG, Tanner CM, Klawans HL. Drug holiday in the management of Parkinson's disease. Clin Neuropharmacol 1982;5:351-64.
8. Kofman OS. Are levodopa "drug holidays" justified? Can J Neurol Sci 1984;11:Suppl:206-9.
9. Feldman RG, Kaye JA, Lannon MC. Parkinson's disease: follow-up after "drug holiday." J Clin Pharmacol 1986;26:662-7.
10. Kurlan R, Tanner CM, Goetz C, et al. Levodopa drug holiday versus drug dosage reduction in Parkinson's disease. Clin Neuropharmacol 1994; 17:117-27.
11. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988;15:32-4.
12. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, 1992:241-51.
13. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
14. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
15. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59:Suppl 3:3-7.
16. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235:60-4.
17. Bear D, Lawson W, Burns S, Tacke U. Clozapine in idiopathic Parkinsons. Biol Psychiatry 1989;25:Suppl:163a. abstract.
18. Bernardi F, Del Zompa M. Clozapine in idiopathic Parkinson's disease. Neurology 1990;40:1151-2.
19. Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardosa F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995;7:471-5.
20. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-31.
21. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44:544-6.
22. Friedman JH, Max J, Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clin Neuropharmacol 1987;10:470-5.
23. Friedman JH, Lannon MC, Caley C. Clozapine for movement disorder patients: a retrospective analysis of 38 patients. Ann Neurol 1992;32: 277. abstract.
24. Gonski PN. The use of clozapine in Parkinson's disease. Aust N Z J Med 1994;24:585.
25. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-6.
26. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-700.
27. Lanazasoro G, Suerez JA, Marti Masso JF. Clozapine in Parkinson's disease: three years experience. Mov Disord 1992;7:Suppl 1:100. abstract.
28. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993;41:669-71.
29. Ostergaard K, Dupont E. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand 1988;78:349-50.
30. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239-42.
31. Pinter MM, Helscher RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neurol Transm Park Dis Dement Sect 1993;5:135-46.
32. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-4.
33. Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989;1:190-2.
34. Rosenthal SH, Fenton ML, Harnett DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hosp Psychiatry 1992;14:285-6.
35. Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F. Low-dose of clozapine in the treatment of dopamincrgic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20:204-9.
36. Rui Silva M, Magalhaes M, Viscu M, Bastos Lima A. Clozapine in the treatment of psychosis in parkinsonism. J Neurol 1995;242:Suppl 2:S138. abstract.
37. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13:377-82.
38. Wagner ML, Defilippi JL, Menza MA, Sage JI. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-80.
39. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992;53:373-6.
40. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994;344:681.
41. Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50:1195-6.
42. Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997;12:610-2.
43. Jimenez-Jimenez FJ, Talon Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998; 50:1183-4.
44. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-9.
45. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-7.
46. Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's synopsis of psychiatry. 7th ed. Baltimore: Williams & Wilkins, 1994.
47. Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. Rockville, Md.: Alcohol, Drug Abuse, and Mental Health Administration, 1976:217-22. (DHEW publication no. (ADM) 76-338.)
48. Lang AET, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309.
49. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-98.
50. Andreason NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
51. Overall JE, Gorham DR. Introduction - the Brief Psychiatric Rating Scale (BPRS): recent developments. Psychopharmacol Bull 1988;21:97-9.
52. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
53. Schwab RS, England AC Jr. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IM, eds. Third Symposium on Parkinson's Disease held at the Royal College of Surgeons of Edinburgh on 20, 21, and 22 May 1968. Edinburgh, Scotland: E. & S. Livingstone, 1969:152-7.
54. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-7.
55. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-9.
56. Fischer PA, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neurol Transm Park Dis Dement Sect 1990;2:233-8.
57. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-5.
58. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-81.
59. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:260-80.
60. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-7.
61. Mindham RHS. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33:188-91.
62. Celesia GC, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200.
63. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971; 218:1915-20.
64. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970;2:177-9.
65. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.
66. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67.
67. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40:832-4.
68. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-Kl cells. Eur J Pharmacol 1991;192:205-6.
69. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.